Soluble Regulators of Interleukin-1 Signaling: Novel Biomarkers for Early Acute Myocardial Infarction Diagnosis and to Predict Ischemia/reperfusion Injury?

Menglong Wang,Jun Wan
DOI: https://doi.org/10.1016/j.ijcard.2018.07.146
IF: 4.039
2019-01-01
International Journal of Cardiology
Abstract:Recently, two different groups proved that baseline levels of soluble regulators of Interleukin (IL)-1 signaling predicted outcomes of coronary artery disease (CAD). Schofer N and colleagues' study demonstrated that circulating IL-1 receptor antagonist (IL1-Ra) is an independent predictor for adverse outcome in patients with documented CAD [ [1] Schofer N. Ludwig S. Rubsamen N. Schnabel R. Lackner K.J. Ruprecht H.J. et al. Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease. Int. J. Cardiol. 2018; 257: 24-29 Abstract Full Text Full Text PDF PubMed Scopus (14) Google Scholar ]. Orrem HL and colleagues' study demonstrated that levels of soluble IL-1 receptors 2 (sIL-1R2) are independently associated with parameters of LV adverse remodeling in STEMI patients [ [2] Orrem H.L. Shetelig C. Ueland T. Limalanathan S. Nilsson P.H. Husebye T. et al. Soluble IL-1 receptor 2 is associated with left ventricular remodelling in patients with ST-elevation myocardial infarction. Int. J. Cardiol. 2018; 268: 187-192 Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar ]. Both IL-1Ra and sIL-1R2 are factors which can attenuate IL-1 signaling and their levels could be indirect indicators for severity of inflammation [ [3] Garlanda C. Dinarello C.A. Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013; 39: 1003-1018 Abstract Full Text Full Text PDF PubMed Scopus (1307) Google Scholar ]. These two studies validated that soluble regulators of IL-1 signaling could be novel biomarkers to predict LV remodeling and prognosis in CAD.
What problem does this paper attempt to address?